---
title: First CE-marked NAD+ analysis kit to the market
description: NADMED has announced it is bringing Q-NADMED and Q-NAD to the market.
image: https://news.lifesciencenewswire.com/hubfs/Q-NADMED%20technology%20is%20based%20on%20colorimetric%20quantification%2c%20even%20from%20blood.jpg
---

[![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/)

- [Newsroom](https://news.lifesciencenewswire.com/newsroom)
- [Back to the main site](https://lifesciencenewswire.com/)

![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1")

# Newsroom

#### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow")

#### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg)

![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg)

### Choose a Category

- [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture)
- [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry)
- [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing)
- [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma)
- [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing)
- [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology)
- [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture)
- [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics)
- [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research)
- [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials)
- [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it)
- [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor)
- [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19)
- [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory)
- [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development)
- [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment)
- [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients)
- [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage)
- [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry)
- [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory)
- [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science)
- [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare)
- [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management)
- [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science)
- [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing)
- [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science)
- [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology)
- [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control)
- [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging)
- [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech)
- [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics)
- [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology)
- [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma)
- [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy)
- [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research)
- [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary)
- [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water)

See all

### Subscribe to Email Updates

- ##### SHARE
- <https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Ffirst-ce-marked-nad-analysis-kit-to-the-market>
- <https://www.twitter.com/share?url=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Ffirst-ce-marked-nad-analysis-kit-to-the-market>
- <http://www.linkedin.com/shareArticle?mini=true&url=https://news.lifesciencenewswire.com/newsroom/first-ce-marked-nad-analysis-kit-to-the-market>

# [First CE-marked NAD+ analysis kit to the market](https://news.lifesciencenewswire.com/newsroom/first-ce-marked-nad-analysis-kit-to-the-market)

 June 29, 2022

[![Q-NADMED technology is based on colorimetric quantification, even from blood](https://news.lifesciencenewswire.com/hs-fs/hubfs/Q-NADMED%20technology%20is%20based%20on%20colorimetric%20quantification%2c%20even%20from%20blood.jpg?width=426&name=Q-NADMED%20technology%20is%20based%20on%20colorimetric%20quantification%2c%20even%20from%20blood.jpg)](https://drive.google.com/file/d/1k43WFiveZ5QeH3RkYBHIJymyHbgSMpyR/view?usp=sharing)NADMED brings two kits to the market: Q-NADMED and Q-NAD. Q-NADMED is the first kit available for whole blood NAD+ and NADH analysis; the first CE-marked kit for NAD analysis; and the only EU IVDD compliant kit for NAD+ and NADH analysis from blood to enter the market.

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites, allowing excellent accuracy comparable to mass spectrometry. Q-NAD kits use the same approach for the four NAD metabolites: NAD+, NADH, NADP, and NADPH.

The lack of a quick and reliable method has been a challenge for measuring NAD+, a molecule that is a major metabolism regulator. NADMED technology offers a unique, scalable, and cost-effective solution to extract all NAD metabolites and eliminate inaccuracies in the individual measuring process. This technology also saves time: While mass spectrometer analysis takes days, NADMED analysis is ready in four hours. Furthermore, NADMED brings the analysis accessible to laboratories without access to mass spectrometry, with only a fraction of mass spectrometer’s total costs.

“NADMED’s technology has been under rigorous development for the past three years, and now it’s come to fruition. We believe the NADMED method will advance science and medical practice by enabling larger and quicker clinical trials and, in due course, diagnostics. NAD measuring should be seen as a first-line diagnostic tool in the future to fight, for example, degenerative diseases and metabolic disorders,” says Jari Närhi, CEO of NADMED Ltd.

Recent studies at Helsinki University show that patients with mitochondrial muscle disease had NAD deficiency detectable in blood and benefited remarkably from NAD booster treatment. “NAD analysis from blood is a very important new tool to detect NAD deficiency, find correct dosing of NAD boosters, and follow up the treatment,” says Anu Suomalainen Wartiovaara, Academy Professor of Clinical Molecular Medicine at Helsinki University and a NADMED Ltd. co-founder.

NADs (nicotinamide adenine dinucleotides) are coenzymes essential for metabolism, regulating hundreds of biochemical reactions in all our cells. NADs exist in four types — NAD+, NADH, NADP+, and NADPH — the ratios of which signal nutrient availability and cellular growth and repair in different cells and tissues. NADs are necessary for all living creatures — from the plant world to the animal kingdom.

For more information, please visit [www.nadmed.com](http://www.nadmed.com).

ABOUT NADMED LTD

NADMED Ltd. is a start-up founded by Helsinki University . NADMED offers kits and laboratory services for the accurate, quick, and cost-effective measurement of NADs from any biological sample, including blood.

 Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials)

##### Browse more news

## Recent releases

<https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai>

#### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

 July 6, 2026

Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

<https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale>

#### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

 June 16, 2026

New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

<https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer>

#### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

 June 16, 2026

Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse")

Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225 

#### Useful information

- [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/)
- [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions)
- [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)